CYFRA21-1、SCCA、NSE、CEA及SII联合检测在慢性阻塞性肺疾病合并肺癌筛查中的应用研究

高军 （河1, 李 翠芳2, 王 亚青3, 王金 荣*3
1、
2、河北医科大学研究生学院
3、石家庄市人民医院

摘要


目的：探讨肿瘤标志物细胞角蛋白19片段（CYFRA21-1）、鳞状细胞癌抗原（SCCA）、神经元特异性烯醇化酶（NSE）、癌胚抗原（CEA）及全身免疫炎症指数（SII）联合检测在慢性阻塞性肺疾病合并肺癌（COPD-LC）筛查中的应用价值。方法：选取72例COPD-LC患者作为观察组，同期收治的82例COPD患者作为对照组。所有患者均入院后第二天采集空腹静脉血检测CYFRA21-1、SCCA、NSE、CEA及SII水平，并收集患者的临床和病理资料，比较两组患者一般情况及血清学指标变化；绘制ROC曲线，分析血清CYFRA21-1、SCCA、NSE、CEA、SII单独检测及联合检测诊断COPD-LC的应用价值。结果：观察组中最常见的病理类型为鳞癌（50.0%），病变多位于上叶（58.3%），Ⅲ期及Ⅳ期的患者比例高达77.8%；观察组血清CYFRA21-1、SCCA、NSE、CEA及SII水平显著高于对照组，差异有统计学意义（P＜0.05）；绘制ROC曲线分析显示，血清CYFRA21-1、SCCA、NSE、CEA、SII单独检测及联合检测诊断COPD-LC的曲线下面积（AUC）分别为0.779、0.707、0.697、0.673、0.889，联合检测诊断价值最高。结论：血清CYFRA21-1、SCCA、NSE、CEA及SII联合检测在COPD-LC筛查中应用价值高，可提高诊断效能，便于临床早期筛查工作开展。

关键词


慢性阻塞性肺疾病；肺癌；肿瘤标志物；全身免疫炎症指数；联合检测

全文:

PDF


参考


[1]Zhou C, Qin Y, Zhao W, et al. International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease [J]. Transl Lung Cancer Res, 2023, 12(8): 1661-1701.

[2]Forder A, Zhuang R, Souza VGP, et al. Mechanisms Contributing to the Comorbidity of COPD and Lung Cancer [J]. Int J Mol Sci, 2023, 24(3).

[3]Husebø GR, Nielsen R, Hardie J, et al. Risk factors for lung cancer in COPD - results from the Bergen COPD cohort study [J]. Respir Med, 2019, 152: 81-88.

[4]Ma H, Zhang Q, Zhao Y, et al. Molecular and Clinicopathological Characteristics of Lung Cancer Concomitant Chronic Obstructive Pulmonary Disease (COPD) [J]. Int J Chron Obstruct Pulmon Dis, 2022, 17: 1601-1612.

[5]Machida H, Inoue S, Shibata Y, et al. The Incidence and Risk Analysis of Lung Cancer Development in Patients with Chronic Obstructive Pulmonary Disease: Possible Effectiveness of Annual CT-Screening [J]. Int J Chron Obstruct Pulmon Dis, 2021, 16: 739-749.

[6]Criner GJ, Agusti A, Borghaei H, et al. Chronic Obstructive Pulmonary Disease and Lung Cancer: A Review for Clinicians [J]. Chronic Obstr Pulm Dis, 2022, 9(3): 454-476.

[7]de-Torres JP, Casanova C, Marín JM, et al. Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study [J]. Respir Med, 2013, 107(5): 702-707.

[8]Nooreldeen R, Bach H. Current and Future Development in Lung Cancer Diagnosis [J]. Int J Mol Sci, 2021, 22(16).

[9]Biswas T, Kang KH, Gawdi R, et al. Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC) [J]. Int J Environ Res Public Health, 2020, 17(21).

[10]Zuo H, Xie X, Peng J, et al. Predictive Value of Novel Inflammation-Based Biomarkers for Pulmonary Hypertension in the Acute Exacerbation of Chronic Obstructive Pulmonary Disease [J]. Anal Cell Pathol (Amst), 2019, 2019: 5189165.

[11]Liu X, Ge H, Feng X, et al. The Combination of Hemogram Indexes to Predict Exacerbation in Stable Chronic Obstructive Pulmonary Disease [J]. Front Med (Lausanne), 2020, 7: 572435.

[12]Huang W, Luo J, Wen J, et al. The Relationship Between Systemic Immune Inflammatory Index and Prognosis of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review [J]. Front Surg, 2022, 9: 898304.

[13]Guo H, Zhou X, Lu Y, et al. Translational progress on tumor biomarkers [J]. Thorac Cancer, 2015, 6(6): 665-671.

[14]中华医学会呼吸病学分会慢性阻塞性肺疾病学组，中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南（2021年修订版）[J].中华结核和呼吸杂志，2021（03）：170-205.

[15]Travis WD, Brambilla E, Burke AP, et al. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart [J]. J Thorac Oncol, 2015, 10(9): 1240-1242.

[16]Detterbeck FC, Franklin WA, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer [J]. J Thorac Oncol, 2016, 11(5): 651-665.

[17]Ye C, Yuan L, Wu K, et al. Association between systemic immune-inflammation index and chronic obstructive pulmonary disease: a population-based study [J]. BMC Pulm Med, 2023, 23(1): 295.

[18]Keit E, Coutu B, Zhen W, et al. Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer [J]. Ann Transl Med, 2021, 9(3): 227.

[19]王丹，庞敏.慢性阻塞性肺疾病合并肺癌的临床特征分析[J].临床肺科杂志，2019，24（06）：1082-1085.

[20]Zhang Q, Cai G, Cui F, et al. The relationship of airflow limitation with lung squamous cell carcinoma: evidence from mendelian randomization analysis [J]. J Cancer Res Clin Oncol, 2023, 149(10): 6999-7006.

[21]Bozinovski S, Vlahos R, Anthony D, et al. COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link [J]. Br J Pharmacol, 2016, 173(4): 635-648.

[22]Mouronte-Roibás C, Fernández-Villar A, Ruano-Raviña A, et al. Influence of the type of emphysema in the relationship between COPD and lung cancer [J]. Int J Chron Obstruct Pulmon Dis, 2018, 13: 3563-3570.

[23]苑静怡.127例慢性阻塞性肺疾病合并肺癌的临床特征分析[D]：吉林大学，2022.

[24]Qu T, Zhang J, Xu N, et al. Diagnostic value analysis of combined detection of Trx, CYFRA21-1 and SCCA in lung cancer [J]. Oncol Lett, 2019, 17(5): 4293-4298.

[25]张静静.探讨血清CA125、NSE及CEA联合检测与慢性阻塞性肺疾病合并肺癌的相关性及中医证型研究[D]：新疆医科大学，2023.

[26]赛亚飞.血清肿瘤标志物CEA、NSE、CA125、CYFRA21-1在周围型支气管肺癌临床诊断中的价值分析[D]：河南大学，2019.

[27]Okamura K, Takayama K, Izumi M, et al. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer [J]. Lung Cancer, 2013, 80(1): 45-49.

[28]Li L, Zhang Q, Wang Y, et al. Evaluating the diagnostic and prognostic value of serum TuM2-PK, NSE, and ProGRP in small cell lung cancer [J]. J Clin Lab Anal, 2023, 37(7): e24865.

[29]Bi H, Yin L, Fang W, et al. Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer [J]. Lab Med, 2023, 54(4): 372-379.

[30]侯娟，陈焕文.癌胚抗原与神经元特异性烯醇化酶等肿瘤标志物联合检测对肺癌的诊断价值[J].中国卫生工程学，2023，22（03）：335-337.


Refbacks

  • 当前没有refback。